TXG Stock Chart & Stats
$1100.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1100.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$214.00 - $1,100.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$151.77B
Enterprise Value$4.51K
Total Cash (Recent Filing)$552.03M
Total Debt (Recent Filing)$78.80M
Price to Earnings (P/E)―
Beta-0.38
Next Earnings
Nov 04, 2026EPS Estimate
-4.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding120,212,296
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.56
Price to Sales (P/S)3.17
P/FCF Ratio15.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$903.99Price Target Upside-17.82% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-12.58
Revenue Forecast (FY)$10.50B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthConsumables growth supports the platform model because recurring assay usage can expand after instruments are placed. Strength in both single-cell and spatial workflows indicates continued customer activity and provides a more durable revenue base than instrument sales alone.
Atera Commercial TractionAtera’s early order strength suggests meaningful customer demand for the new spatial whole-transcriptome platform. If converted into installations and recurring experiments, the product can broaden adoption, increase consumables pull-through, and support longer-term growth.
Strong Liquidity And Low LeveragePositive operating and free cash flow, combined with low leverage, gives 10x Genomics financial flexibility to fund product development, commercial expansion, and strategic initiatives. This reduces reliance on external capital while the company works toward consistent profitability.
Bears Say
Persistent Losses And Revenue SoftnessThe company has not yet established durable profitability or consistent top-line growth. Ongoing net losses can limit internally funded investment and make operating performance more sensitive to research budgets, customer purchasing cycles, and the pace of platform adoption.
Sharp Instrument Revenue DeclineThe steep instrument decline shows that the transition to newer spatial products is disrupting the capital-equipment portion of the model. Lower placements can slow installed-base expansion and defer the future consumables revenue that depends on active instruments.
Atera Shipment ConstraintsProduction limits prevent the company from converting current Atera demand into installations as quickly as customers are ordering. This delays instrument revenue and the associated consumables opportunity, creating execution risk during an important product transition.
10x Genomics News
TXG FAQ
What was 10x Genomics Inc’s price range in the past 12 months?
10x Genomics Inc lowest stock price was $214.00 and its highest was $1100.00 in the past 12 months.
What is 10x Genomics Inc’s market cap?
10x Genomics Inc’s market cap is $151.77B.
When is 10x Genomics Inc’s upcoming earnings report date?
10x Genomics Inc’s upcoming earnings report date is Nov 04, 2026 which is in 51 days.
How were 10x Genomics Inc’s earnings last quarter?
10x Genomics Inc released its earnings results on Aug 06, 2026. The company reported -$2.368 earnings per share for the quarter, beating the consensus estimate of -$4.11 by $1.742.
Is 10x Genomics Inc overvalued?
According to Wall Street analysts 10x Genomics Inc’s price is currently Overvalued.
Does 10x Genomics Inc pay dividends?
10x Genomics Inc does not currently pay dividends.
What is 10x Genomics Inc’s EPS estimate?
10x Genomics Inc’s EPS estimate is -4.4.
How many shares outstanding does 10x Genomics Inc have?
10x Genomics Inc has 120,212,296 shares outstanding.
What happened to 10x Genomics Inc’s price movement after its last earnings report?
10x Genomics Inc reported an EPS of -$2.368 in its last earnings report, beating expectations of -$4.11. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of 10x Genomics Inc?
Currently, no hedge funds are holding shares in MX:TXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
10x Genomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$903.99 (-17.82% Downside)
$903.99 (-17.82% Downside)
Blogger Sentiment
Neutral
MX:TXG Sentiment 64%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth $93.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
425.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
10x Genomics Inc
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
TXG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a constructive mix of operational positives — notably Atera's outsized early demand, solid consumables growth (+7% total; spatial +16%), gross margin expansion to 74%, and a raised full‑year revenue guide — while flagging near‑term cadence challenges driven by instrument revenue declines (‑47%) and manufacturing/shipment constraints for Atera that produce an expected Q3 sequential dip. The business shows healthy underlying consumable momentum and strategic positioning (M&A, multi‑omics, AI tailwinds), but short‑term instrument timing and APAC comparatives introduce visibility headwinds.View all MX:TXG earnings summariesTXG Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China
TXG Stock 12 Month Forecast
Average Price Target
$903.99
▼(-17.82% Downside)